Professional Summary

Professional Overview

Erik Mai is an accomplished corporate development professional with extensive experience in the biotechnology industry. He currently serves as the Director of Corporate Development at Moderna, where he plays a pivotal role in shaping the company's strategic initiatives and driving business growth.

Experience Summary

Current Role

As the Director of Corporate Development at Moderna, Erik is responsible for identifying and evaluating strategic opportunities, including mergers, acquisitions, partnerships, and licensing agreements. He works closely with cross-functional teams to analyze market trends, assess potential targets, and negotiate and structure transactions that align with Moderna's long-term objectives. Under his leadership, Erik has successfully executed several high-impact deals that have significantly expanded the company's pipeline and product portfolio.

Career Progression

Prior to his current role, Erik held various positions within the biotechnology industry, including Associate Director of Business Development and Strategy at Moderna, Associate Director of Strategy and Portfolio at Intellia Therapeutics, and Strategy and Operations Consultant at Flagship Pioneering. His diverse experience in strategy, business development, and operations has equipped him with a comprehensive understanding of the industry's dynamics and the ability to drive complex, cross-functional initiatives.

Academic Background

Erik holds a Master of Business Administration (MBA) degree from Harvard Business School, where he specialized in healthcare and life sciences. He also earned a Bachelor of Science (BS) degree in Biological Engineering from the Massachusetts Institute of Technology (MIT).

Areas of Expertise

• Corporate strategy and business development

• Mergers, acquisitions, and strategic partnerships

• Market analysis and competitive intelligence

• Financial modeling and transaction structuring

• Cross-functional collaboration and project management

Professional Impact

Throughout his career, Erik has demonstrated a track record of driving successful business outcomes. At Moderna, he has played a key role in expanding the company's pipeline and product portfolio through strategic transactions, contributing to the organization's overall growth and industry leadership. Erik's deep industry knowledge, analytical acumen, and collaborative approach have made him a valuable asset to the Moderna team.

Conclusion

With his extensive expertise in corporate development and his proven ability to navigate the complex biotechnology landscape, Erik Mai is well-positioned to continue driving Moderna's strategic initiatives and contributing to the company's long-term success. His commitment to innovation and his passion for advancing the field of biotechnology make him a valuable asset to the industry.